CGC Genomics, founded in 2023, develops Qnomx, a regulatory‑grade generative AI platform that interprets NGS cancer genome reports and produces concise, clinically relevant summaries with a human‑in‑the‑loop. The company is developing Qnomx under an ISO 13485‑certified quality management system and aims for regulatory approval compliant with IVDR, MDR and the European AI Act. Internal use has shown substantial efficiency gains—reducing manual interpretation that can take up to two hours to concise summaries delivered in minutes—and the platform is now in pilot validation with Labor Becker and the OnkoMedeor Group. CGC positions Qnomx as a transparent, auditable alternative to unregulated tools currently used in some clinical settings. The startup highlights the market need—rising cancer cases and low NGS uptake—where many oncologists find current NGS reports too complex to act on quickly. Financially, CGC Genomics has secured external support via a pre‑Seed raise to advance product development and regulatory milestones.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025